J&J aims to expand Darzalex's use even further in the blood cancer, while Merck & Co. and Novo Nordisk presented at ASH ...

For patients with transplant-ineligible or -deferred newly diagnosed multiple myeloma, the addition of Darzalex to VRd ...

Based on DREAMM-7 and another positive phase 3 trial, DREAMM-8 for Blenrep’s combination with Bristol Myers Squibb’s Pomalyst ...

Price increases for five of the 10 drugs that contributed the most to a rise in U.S. medical spending in 2023 were not ...

GSK's Blenrep combo demonstrates significant survival benefits and improved efficacy in relapsed multiple myeloma compared to ...

Health care stocks have underperformed in recent months on uncertainty surrounding the incoming Donald Trump administration, but they can often be a solid defensive play in an uncertain economy.

Price increases for five of the 10 drugs that contributed the most to a rise in U.S. medical spending in 2023 were not ...

Yet, innovative Medicine unit is performing at above-market levels. Growth is being driven by existing products like Darzalex, Tremfya and Erleada and also continued uptake of new launches, including ...

The risk for disease progression or death was reduced by 51% with subcutaneous Darzalex Faspro in certain patients with ...

Johnson & Johnson (JNJ) announced data highlighting that DARZALEX FASPRO (daratumumab and hyaluronidase-fihj)-based regimens improve ...

Market analysts liked the news, with analysts for Cantor writing that this was a “best-case data update.” ...

GlobalData’s patient-based forecast predicts Tecvayli will reach a peak of $2.1bn in sales globally by 2030 in MM.